A bidding war is brewing over $50 billion drugmaker Shire (SHPG, TKPYY, AGN)

Shire rejected Takeda's $60 billion takeover bid on Thursday morning. Allergan then confirmed it was "in the early stages of considering a possible offer" for Shire, potentially creating a bidding wa.....»»

Reuters Takeda has reached a deal to buy Adderall drugmaker Shire for $64.3 billion.  The deal comes after a handful of rejections from Shire and a short-lived potential for a bidding war between Takeda and Botox-maker Allergan.&.....»»

A potential bidding war for drugmaker Shire erupted after Japan’s Takeda said it made a $60 billion takeover offer and U.S. rival Allergan said it was considering making its own bid......»»

The drugmaker’s blockbuster deal for Alexion marks a departure, but deserves the benefit of the doubt. A bidding war would complicate things......»»

Takeda Pharmaceutical Co Ltd agreed to sell its dry eye drug to Swiss drugmaker Novartis AG for $3.4 billion and potential milestone payments of up to $1.9 billion, in the first divestment since its takeover of Britain's Shire......»»

Takeda is near a deal worth more than $60 billion to buy European drugmaker Shire, having raised its bid four times in a sign of how ardently Japan’s legacy companies are pursuing growth abroad as sales at home slow......»»

Japanese drugmaker Takeda has reached a tentative agreement to buy Ireland-based Shire for 46 billion pounds......»»

LONDON/NEW YORK (Reuters) - London-listed drugmaker Shire Plc said it was willing to recommend a deal with Takeda Pharmaceutical Co to its shareholders, after the Japanese company sweetened its acquisition offer to 46 billion pounds ($64 billion)......»»

(Reuters) - London-listed drugmaker Shire Plc and Japan's Takeda Pharmaceutical Co Ltd plan to announce a preliminary deal on Wednesday, after the latter sweetened its $62 billion acquisition offer, people familiar with the matter said......»»

Takeda made a fifth takeover proposal for rival drugmaker Shire, a last-ditch move by the Japanese company that would likely value the rare-drug specialist at more than $60 billion......»»

Shares in drug company Shire surged in London as Japan's Takeda and Allergan consider bidding......»»

Shire has already rebuffed a $62.5 billion offer from Japan's Takeda. In what would make for.....»»

NEW YORK/LONDON (Reuters) - Drugmaker Shire has rejected a third takeover bid worth nearly $63 billion from Japan's Takeda Pharmaceutical , although talks are continuing, while sources said Allergan was also in competing negotiations......»»

LONDON (Reuters) - Takeda Pharmaceutical has made a bid for Shire that values the London-listed drugmaker at around $61 billion, two sources with direct knowledge of the matter told Reuters......»»

LONDON (Reuters) - Shire , the $47 billion rare disease drugmaker being stalked by Japan's Takeda Pharmaceutical , faces fresh criticism over its executive pay policy from a leading investor advisory group as a crunch week approaches......»»

Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. T.....»»

Shire has agreed to sell its oncology business to French drugmaker Servier for $2.4 billion, in a deal that could discourage Takeda from launching a takeover......»»

Shire has agreed to sell its oncology business to French drugmaker Servier for $2.4 billion, in a deal that could discourage Takeda from launching a takeover......»»

LONDON (Reuters) - Shire , the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical , is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion......»»

Japanese drugmaker Takeda has agreed to buy Ireland-based Shire for 46 billion pounds ($62.4 billion) in one of the biggest pharma deals to date......»»